New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Cipla completes transfer of Generics Business Undertaking
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Subscribe To Our Newsletter & Stay Updated
